A new product that could keep people alive with a heart transplant has been unveiled at the annual International Conference on Cardiovascular Disease.
MMB, a global medical device company, announced its new heart transplant product that can be administered by a cardiologist.
The new product, called MMB sterlite, is based on an algorithm developed by MMB and is the first time a heart tissue-injection system is based in-house.
Dr. David Naylor, MMB president and CEO, said the system could be used to help prevent the spread of the virus to those who need it.
“The MMB system can potentially save lives by lowering the risk of heart failure and potentially prolonging survival of patients in high-risk areas,” Dr. Naylor said in a statement.
At least 1.2 million Americans have died from the coronavirus, according to data from the Centers for Disease Control and Prevention.
More than 50,000 patients have died of the disease in the United States so far, according the CDC.
To get the new product off the ground, Mmb and its medical device partner MMB Technologies teamed up with a medical device maker called Sysco and the biotechnology company Axos Pharmaceuticals to develop a system that can deliver the new transplant, according a press release.
Sysco, which is based near Austin, Texas, is a leading biotechnology and medical device supplier.
Axos is based out of Boston.
In addition to MMB, Axos also owns BiotechBionics, a company that makes the implant for MMB.
According to the press release, the new implant is based off of an existing implant that MMB has in-built, which uses an external implant device that is implanted into the body.
The new implant uses a combination of a gene-editing technique and a protein called a caspase-3 enzyme that can trigger an immune response in the body to prevent the infection from spreading.
This new technology, according its press release said, can deliver an implant into the heart of a patient who has died of an underlying heart disease.
In addition, the company said the new heart implant system is currently being tested in an animal model in which the virus was killed off by administering the new MMB-Sterlite technology, which allows the patient to remain alive without the need for blood transfusions.
The MIB sterlite system is being developed by the company’s team in collaboration with a research institute at MIT.
Axos is also developing a technology to deliver a cardiac pacemaker that is similar to the MMB heart implant, but can also deliver a pacemaker in the blood stream.